» Articles » PMID: 2469503

Regulation of Expression of a Human Intercellular Adhesion Molecule (ICAM-1) During Lymphohematopoietic Differentiation

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1989 May 15
PMID 2469503
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

The intercellular adhesion molecule (ICAM-1) is a cell-surface molecule which binds to leukocyte function antigen-1 (LFA-1) and regulates both leukocyte adhesion to endothelial cells and immune functions requiring cell-cell contact. Membrane expression of ICAM-1 is highly regulated on all hematopoietic lineages. Cell membrane antigen is significantly expressed on a small subset of bone marrow (BM) progenitors but is weak or absent on all cell lineages once they enter the circulation. However, strong expression on tissue macrophages and germinal center B cells suggested that activated cells may show upregulated expression. When B cells, T cells, macrophages, or granulocytes were activated in vitro by suitable mitogens, ICAM-1 expression was induced in all cases. Parallel studies of hematopoietic tumors demonstrated a heterogeneity of expression which correlated with expression on their normal cellular counterparts. In particular, a striking correlation between expression on B-cell tumors and corresponding stages of B-cell differentiation was noted. The widely varying expression of ICAM-1 contrasts with LFA-1 which, while variable, is nevertheless significantly positive at all stages of differentiation. This suggests that the major regulation of homotypic adhesion mediated by the LFA-1/ICAM-1 linkage occurs through control of ICAM-1 expression. In keeping with this notion, ICAM-1 expression was also correlated with the "adhesiveness" of B-lymphoid tumors. Large solitary lymphoma masses showed intense expression of ICAM-1. Conversely, chronic lymphocytic leukemia (CLL) cells and lymphoma cells from tumors exhibiting diffuse, widespread lymph node disease showed weak expression. These observations are discussed in relation to the role of ICAM-1 in regulation of lymphoid recirculation and the biology of lymphoid tumors.

Citing Articles

Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma.

Sherbenou D, Su Y, Behrens C, Aftab B, Perez de Acha O, Murnane M Clin Cancer Res. 2020; 26(22):6028-6038.

PMID: 32917735 PMC: 7669584. DOI: 10.1158/1078-0432.CCR-20-0400.


ICAM-1-expressing neutrophils exhibit enhanced effector functions in murine models of endotoxemia.

Woodfin A, Beyrau M, Voisin M, Ma B, Whiteford J, Hordijk P Blood. 2015; 127(7):898-907.

PMID: 26647392 PMC: 4863345. DOI: 10.1182/blood-2015-08-664995.


Monocytic cell differentiation from band-stage neutrophils under inflammatory conditions via MKK6 activation.

Koffel R, Meshcheryakova A, Warszawska J, Hennig A, Wagner K, Jorgl A Blood. 2014; 124(17):2713-24.

PMID: 25214442 PMC: 4536888. DOI: 10.1182/blood-2014-07-588178.


Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells.

Wang L, Shi W, Yang F, Tang W, Gapihan G, Varna M Haematologica. 2011; 96(6):927-31.

PMID: 21330328 PMC: 3105657. DOI: 10.3324/haematol.2010.037689.


Adhesion of Epstein-Barr virus-positive natural killer cell lines to cultured endothelial cells stimulated with inflammatory cytokines.

Kanno H, Watabe D, Shimizu N, Sawai T Clin Exp Immunol. 2008; 151(3):519-27.

PMID: 18190605 PMC: 2276960. DOI: 10.1111/j.1365-2249.2007.03584.x.